Amifostine - (Mar 1996) -Chemotheraphy agentsDrug Name:
Amifostine - (Mar 1996) -Chemotheraphy agents
List Of Brands:
Indication Type Description:
Dosages/ Overdosage Etc
Interaction with Food
Pregnancy and lactation
Concurrent use with antihypertensives may cause severe hypotension
Hypotension during infusion.
Systolic fall is greater.
Transient & reversible loss of consciousness
Nausea, vomiting, Flushing, feeling of warmth, Chills, dizziness,
Sneezing, hiccoughs, & Drowsiness, Mild skin rashes.
Hypersensitivity, patients with low blood pressure, dehydration, pregnancy, nursing mothers, patients with renal or hepatic impairment, children and elderly over 70 years.
Patients should be well hydrated & kept supine during amifostine infusion which should be given within15 minutes. Prolonged infusion causes greater side effects .
Antihypertensive drugs should be stopped 24 before infusion.
BP should be monitored.
Antiemetics may be administered before infusion epecially when emetogenic drugs are used.
Dosages/ Overdosage Etc:
As a cyoprotective agent in chemotherapy
The recommended starting dose for adults is 910mg/m2 administered once daily as an IV infusion over 15 minutes starting within 30 minutes prior to chemotherapy infusions. Blood pressure should be monitored during infusion of amifostine.
Amifostine is a prodrug, and requires conversion by alkaline phosphates to the active metabolite Amifostine shows a much greater protective action in the normal cells because of their higher pH and the higher activity to alkaline phosphates in their cell membranes. This allows greater conversion of amifostine into the active metabloite.
During a 15-minute infusion of 910 mg/m2, the peak plasma concntration of amifostine is approx 200 micromol.L.
The elimination half-life is less than 10 minutes. Less than 4% of amifostine and its metabolites are excreted in the urine.
Interaction with Food:
Reportsd not available
Pregnancy and lactation:
Use contraindicated Observe caution